Open an account

First Trust Nasdaq Pharmaceuticals ETF

FTXH · ETF

$42.68−$0.5224 (−1.21%)TodayMarket closed ·
Prev close $43.20

About FTXH

FTXH was created on 2016-09-20 by First Trust. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 1092.83m in AUM and 51 holdings. FTXH tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth.

Issuer
First Trust
Tracks
Nasdaq US Smart Pharmaceuticals Index
Expense ratio
0.6%
Assets under management
$1.14B
Inception
Sep 20, 2016
Asset class
Equity
Website
ftportfolios.com

FTXH key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
353.51K
Volume
83.52K
Open price
$43.00
High today
$43.00
Low today
$42.42
52 Week high
$43.52
52 Week low
$29.40

First Trust Nasdaq Pharmaceuticals ETF (FTXH) at a glance

As of Oct 23, 2026, First Trust Nasdaq Pharmaceuticals ETF (FTXH) shares are priced at $42.68, giving the company a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $42.42 and $43.00. The current price is 0.6% above the day's low and 0.8% below its high.

Volume so far is 83.52K shares, below the average of 353.51K shares a day.

Over the past year First Trust Nasdaq Pharmaceuticals ETF has ranged from $29.40 to $43.52, and now sits 94% of the way up that range.

FTXH news

  • Kaustubh Bagalkote

    Why Is Eli Lilly Stock Falling Tuesday?

  • Rishabh Mishra

    Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'

  • Rishabh Mishra

    Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

  • Rishabh Mishra

    Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

  • Rishabh Mishra

    Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

  • Rishabh Mishra

    Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

  • Vandana Singh

    Federal Judge Halts National Institutes of Health's Grant Policy Overhaul Citing Legal Violations

  • Chandrima Sanyal

    Bird Flu Sparks Vaccine Stock Surge: ETFs To Watch As H5N1 Outbreak Intensifies

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.